mosipasertib   Click here for help

GtoPdb Ligand ID: 14619

Synonyms: ATRN-119 | ATRN119 | compound P(4) [US20170226130]
Compound class: Synthetic organic
Comment: Mosipasertib is the INN for a serine/threonine kinase inhibitor with antineoplastic potential that was included in WHO INN Proposed List 135 (July 2026). Structure matches exist in patents that claim macrocyclic ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors that are held by Atrin Pharmaceuticals [2], whose lead asset was the orally bioavailable ATR inhibitor ATRN-119. Atrin Pharmaceuticals was subsequently acquired by Aprea Therapeutics. The code name-to-INN association is confirmed on Aprea's pipeline webpage [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 12
Hydrogen bond donors 3
Rotatable bonds 2
Topological polar surface area 165.32
Molecular weight 556.64
XLogP -2.25
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CNCC1=CC=CC2=C1OCCOCCOCCN(C)S(=O)(=O)C3=CC=C(C=C3)C4=NC(=C(N)N=C4)C(=O)N2
Isomeric SMILES C1=2NC(=O)C=3C(N)=NC=C(C=4C=CC(S(=O)(N(CCOCCOCCOC1=C(CNC)C=CC2)C)=O)=CC4)N3
InChI InChI=1S/C26H32N6O6S/c1-28-16-19-4-3-5-21-24(19)38-15-14-37-13-12-36-11-10-32(2)39(34,35)20-8-6-18(7-9-20)22-17-29-25(27)23(30-22)26(33)31-21/h3-9,17,28H,10-16H2,1-2H3,(H2,27,29)(H,31,33)
InChI Key UEOXMKFLURTGRW-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
ATRN-119 was progressed as a clinical stage anti-tumour agent, in both solid tumours and haematological cancers.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04905914 Study Of ATRN-119 In Patients With Advanced Solid Tumors Phase 1/Phase 2 Interventional Aprea Therapeutics
NCT07578467 Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs Phase 1/Phase 2 Interventional Abramson Cancer Center at Penn Medicine
NCT07617363 ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS Phase 1 Interventional Washington University School of Medicine